378 related articles for article (PubMed ID: 36193898)
1. A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap.
Ledwos N; Rosenblat JD; Blumberger DM; Castle DJ; McIntyre RS; Mulsant BH; Husain MI
J Clin Psychopharmacol; 2022 Nov-Dec 01; 42(6):581-588. PubMed ID: 36193898
[TBL] [Abstract][Full Text] [Related]
2. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.
Rosenblat JD; Husain MI; Lee Y; McIntyre RS; Mansur RB; Castle D; Offman H; Parikh SV; Frey BN; Schaffer A; Greenway KT; Garel N; Beaulieu S; Kennedy SH; Lam RW; Milev R; Ravindran AV; Tourjman V; Ameringen MV; Yatham LN; Taylor V
Can J Psychiatry; 2023 Jan; 68(1):5-21. PubMed ID: 35975555
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
[TBL] [Abstract][Full Text] [Related]
4. Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis.
Leger RF; Unterwald EM
J Psychopharmacol; 2022 Jan; 36(1):20-30. PubMed ID: 34519567
[TBL] [Abstract][Full Text] [Related]
5. Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research.
Bender D; Hellerstein DJ
Psychopharmacology (Berl); 2022 Jun; 239(6):1907-1932. PubMed ID: 35022823
[TBL] [Abstract][Full Text] [Related]
6. Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants.
Galvão-Coelho NL; Marx W; Gonzalez M; Sinclair J; de Manincor M; Perkins D; Sarris J
Psychopharmacology (Berl); 2021 Feb; 238(2):341-354. PubMed ID: 33427944
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
[TBL] [Abstract][Full Text] [Related]
8. Psychedelics and Psychedelic-Assisted Psychotherapy.
Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
[TBL] [Abstract][Full Text] [Related]
9. The psychedelic call: analysis of Australian Poisons Information Centre calls associated with classic psychedelics.
Wilkes R; Roberts DM; Liknaitzky P; Brett J
Clin Toxicol (Phila); 2024 Apr; 62(4):242-247. PubMed ID: 38753585
[TBL] [Abstract][Full Text] [Related]
10. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review.
Breeksema JJ; Kuin BW; Kamphuis J; van den Brink W; Vermetten E; Schoevers RA
J Psychopharmacol; 2022 Oct; 36(10):1100-1117. PubMed ID: 36017784
[TBL] [Abstract][Full Text] [Related]
11. [Contribution of serotonin 5-HT
Ibi D
Nihon Yakurigaku Zasshi; 2023 May; 158(3):229-232. PubMed ID: 36990794
[TBL] [Abstract][Full Text] [Related]
12. Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis.
Goldberg SB; Shechet B; Nicholas CR; Ng CW; Deole G; Chen Z; Raison CL
Psychol Med; 2020 Dec; 50(16):2655-2666. PubMed ID: 33143790
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular safety of psychedelic medicine: current status and future directions.
Wsół A
Pharmacol Rep; 2023 Dec; 75(6):1362-1380. PubMed ID: 37874530
[TBL] [Abstract][Full Text] [Related]
14. Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action.
Dos Santos RG; Hallak JE; Baker G; Dursun S
J Psychopharmacol; 2021 Apr; 35(4):453-458. PubMed ID: 33740877
[TBL] [Abstract][Full Text] [Related]
15. Psychedelics for treatment resistant depression: are they game changers?
Kalfas M; Taylor RH; Tsapekos D; Young AH
Expert Opin Pharmacother; 2023; 24(18):2117-2132. PubMed ID: 37947195
[TBL] [Abstract][Full Text] [Related]
16. The acute effects of classic psychedelics on memory in humans.
Healy CJ
Psychopharmacology (Berl); 2021 Mar; 238(3):639-653. PubMed ID: 33420592
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies.
Andersen KAA; Carhart-Harris R; Nutt DJ; Erritzoe D
Acta Psychiatr Scand; 2021 Feb; 143(2):101-118. PubMed ID: 33125716
[TBL] [Abstract][Full Text] [Related]
18. Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review.
Le GH; Wong S; Badulescu S; Au H; Di Vincenzo JD; Gill H; Phan L; Rhee TG; Ho R; Teopiz KM; Kwan ATH; Rosenblat JD; Mansur RB; McIntyre RS
J Affect Disord; 2024 Jun; 355():342-354. PubMed ID: 38570038
[TBL] [Abstract][Full Text] [Related]
19. Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis.
Ko K; Kopra EI; Cleare AJ; Rucker JJ
J Affect Disord; 2023 Feb; 322():194-204. PubMed ID: 36209780
[TBL] [Abstract][Full Text] [Related]
20. A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy.
Luoma JB; Chwyl C; Bathje GJ; Davis AK; Lancelotta R
J Psychoactive Drugs; 2020; 52(4):289-299. PubMed ID: 32529966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
